Jean-Paul Clozel
Chief Executive Officer chez IDORSIA LTD
Postes actifs de Jean-Paul Clozel
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| IDORSIA LTD | Director/Board Member | 01/06/2017 | - |
| Chief Executive Officer | 01/06/2017 | - | |
Idorsia Pharmaceuticals Ltd.
 Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Director/Board Member | 01/01/2017 | - |
| Chief Executive Officer | 01/01/2017 | - |
Historique de carrière de Jean-Paul Clozel
Anciens postes connus de Jean-Paul Clozel
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ACTELION | Director/Board Member | 19/05/2010 | 16/06/2017 |
| Chief Executive Officer | 19/05/2010 | 16/06/2017 | |
| Founder | 30/12/1999 | 16/06/2017 | |
| Corporate Officer/Principal | 27/04/2009 | 19/05/2010 | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/01/1997 | 01/01/1997 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Chairman | - | - |
Actelion Pharmaceuticals UK Ltd.
 Actelion Pharmaceuticals UK Ltd. Medical DistributorsDistribution Services Actelion Pharmaceuticals UK Ltd. discovers, develops, and markets drugs. Its products are Tracleer for the treatment of pulmonary arterial hypertension and Zavesca, which is used to treat Type 1 Gaucher disease. The company is headquartered in London, UK. | Chief Executive Officer | 01/01/1997 | - |
Statistiques
Internationale
| Suisse | 5 |
| Royaume-Uni | 2 |
Opérationnelle
| Chief Executive Officer | 4 |
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
Sectorielle
| Health Technology | 5 |
| Distribution Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IDORSIA LTD | Health Technology |
| Entreprise privées | 4 |
|---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Actelion Ltd.
 Actelion Ltd. Pharmaceuticals: MajorHealth Technology Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland. | Health Technology |
Actelion Pharmaceuticals UK Ltd.
Actelion Pharmaceuticals UK Ltd. Medical DistributorsDistribution Services Actelion Pharmaceuticals UK Ltd. discovers, develops, and markets drugs. Its products are Tracleer for the treatment of pulmonary arterial hypertension and Zavesca, which is used to treat Type 1 Gaucher disease. The company is headquartered in London, UK. | Distribution Services |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Health Technology |
- Bourse
- Insiders
- Jean-Paul Clozel
- Expérience
